Detalles de la búsqueda
1.
Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023.
Clin Infect Dis
; 78(2): 338-348, 2024 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633258
2.
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
N Engl J Med
; 385(15): 1355-1371, 2021 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496194
3.
Treatment Rates for Chlamydia trachomatis and Neisseria gonorrhoeae in a Metropolitan Area: Observational Cohort Analysis.
Sex Transm Dis
; 51(5): 313-319, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301626
4.
Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
J Infect Dis
; 227(12): 1348-1363, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36806690
5.
Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022.
J Infect Dis
; 227(8): 961-969, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36415904
6.
Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness.
Clin Infect Dis
; 76(9): 1615-1625, 2023 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36611252
7.
Findings From a Scoping Review: Presumptive Treatment for Chlamydiatrachomatis and Neisseria gonorrhoeae in the United States, 2006-2021.
Sex Transm Dis
; 50(4): 209-214, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36584164
8.
Investigating the Relation between Electronic Cigarette Use and Sleep Duration in Kentucky Using the BRFSS, 2016-2017.
South Med J
; 116(3): 326-331, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36863057
9.
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
MMWR Morb Mortal Wkly Rep
; 71(29): 931-939, 2022 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35862287
10.
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(9): 352-358, 2022 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35239634
11.
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(7): 255-263, 2022 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35176007
12.
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
MMWR Morb Mortal Wkly Rep
; 71(13): 495-502, 2022 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358170
13.
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
MMWR Morb Mortal Wkly Rep
; 71(42): 1335-1342, 2022 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36264840
14.
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(4): 139-145, 2022 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35085224
15.
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.
MMWR Morb Mortal Wkly Rep
; 70(44): 1539-1544, 2021 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34735425
16.
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
MMWR Morb Mortal Wkly Rep
; 70(44): 1553-1559, 2021 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34735426
17.
Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021.
Am J Transplant
; 22(1): 306-314, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34967121
18.
Increasing Visibility of Sickle Cell Disease in Indiana: Establishing Baseline Prevalence Using Integrated Data From Multiple Sources.
Public Health Rep
; 139(2): 201-207, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37232202
19.
Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.
Influenza Other Respir Viruses
; 18(3): e13269, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494192
20.
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study.
Lancet Reg Health Am
; 23: 100530, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37333688